See cagrilintide dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Cagrilintide is a long-acting amylin analog under active clinical investigation, frequently studied in combination with GLP-1 receptor agonists for metabolic and weight management research. This data captures the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting cagrilintide.
Cagrilintide is a long-acting amylin analog engineered by Novo Nordisk — a modified human amylin sequence with a fatty-acid spacer at Lys26 that pushes the half-life out to roughly 159 hours and supports weekly subcutaneous dosing, which native amylin (and its short-acting analog pramlintide) cannot. 0mg/day and placebo. 8% at 26 weeks versus roughly 3% on placebo — a respectable signal for a single-mechanism amylin agonist, but never the headline figure cagrilintide is now best known for. 4mg semaglutide, which is the entire focus of the Phase 3 REDEFINE series (REDEFINE 1 in obesity, REDEFINE 2 in type 2 diabetes, REDEFINE 4 head-to-head against tirzepatide). 7% at 68 weeks.
Cagrilintide is a long-acting amylin-analog research peptide most often sourced for weight-management research, frequently paired with semaglutide. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Amylin is co-secreted with insulin by pancreatic beta cells and acts on AMY1, AMY2, and AMY3 receptors (calcitonin receptor heterodimers with RAMP1/2/3) in the area postrema and hypothalamic arcuate nucleus to slow gastric emptying, suppress glucagon, and reduce food intake via central satiety pathways. Cagrilintide uses a fatty-acid side-chain to enable albumin binding and extends amylin's half-life from minutes to roughly 159 hours, supporting once-weekly dosing.
A 26-week Phase 2 trial (Lau et al., Lancet 2021) in 706 adults with obesity reported ~10.8% mean weight reduction on cagrilintide 4.5mg monotherapy versus 3.0% on placebo. A Phase 1b combination study with semaglutide (Enebo et al., Lancet 2021) found ~17.1% weight loss at 20 weeks — driving the move to the REDEFINE Phase 3 program comparing CagriSema head-to-head against tirzepatide.
Cagrilintide has a reported half-life of ~7 days, and the dose intervals researchers model most often fall around once weekly. Long-acting amylin analog designed for once-weekly dosing; it reaches a steady level over about 5 weeks, with a lot carrying over week to week. It is catalogued under Weight Loss on WPA.
949 Cagrilintide reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (208 calculations). The median dose across all sessions is 500mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (448 sessions). The most common dosing frequency is once weekly (95 logged protocols), followed by 2x/week (17).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.